CFO Nithya Balasubramananian told Nithya Balasubramananian that the goal of the Inventurus Knowledge Solutions (IKS) supported by the Jhunjhunwala family is to increase synergy by increasing the market’s growth rate in fiscal 26 by making more investments in artificial intelligence (AI). Mint In the interview.
The Mumbai-based company provides technology-led medical solutions to hospitals and clinics in the United States. The industry’s total addressable market in the United States is $222 billion, of which $34 billion is outsourcing.
“This outsourcing market has a growth rate of 12%, and we should be able to grow faster than the market… Given that [our] Business model, we think we should be able to continue to capture market share. ” Balasubramanian said.
IKS Health, listed on the exchange in December, released its financial results for the quarter ended March 31, 2025. The company reported revenue growth of 17% in the 25th quarter to ₹$72.4 billion due to the increase in new customers. The company’s profit after tax is about 133% ₹1.48 million. Its healthy EBITDA margin was 31% in the quarter.
Overall, in fiscal 25, its revenue was ₹2664 million, a year-on-year increase of 47%, and a profit margin of 30%.
“The last quarter saw five outstanding customer wins, including three platform deals, which gave us confidence in the strategy of building a complete platform in a market that is largely composed of Point Solutions Companies,” founder and CEO Sachin K. Gupta said in a press release. Point Solutions Corp. is also known as a single-item company.
The company offers customers 16 features, from optimized patient access schedules to revenue optimization solutions that help companies maximize revenue and more, targeting all of their features that sell to customers. Balasubramanian said there was a rise in people and demand for it.
She said consumers are increasingly choosing IKS Health’s all-round solution, rather than choosing one or two companies and then using other companies.
Driving power of growth
Balasubramanian said the company will focus on AI investments in fiscal 26, adding that it is trying to increase automation of all its products. The company’s total R&D expenditure is approximately 4.5-5.0% of its revenue.
The Trump administration’s focus on cutting health care costs is also a headwind for companies as customers want to reduce costs and improve efficiency.
“From our business perspective, such cost-cutting programs or efficiency survey programs are achievable for us because we are part of the solution,” Balasubramanian said. “Our platform actually enables provider organizations and health systems to deliver their operations more effectively.”
The company has seen an increase in interest and doubts. “The fact that we have been able to push more customers to my platform transactions also shows that the conversation is shifting,” she said.
In addition, the company was able to improve synergy with the entity Aquity Solutions it acquired in FY25. “We have been able to change Aquity’s business model to a large extent,” Subramanian said.
Aquity, which provides clinical documentation, medical coding and income integrity solutions, has 2-3 features instead of the 16 features offered by IKS. Aquity also serves hospitals and medical chains such as IKS Health. “Most of them are delivered in a human-led manner and are mainly onshore. From there, we have been able to deploy a combination of IKS technologies and turn the mixture from land to offshore,” Subramanian said.
Aquity was acquired by IKS in 2023 for a $200 million contract.
While the HealthTech Solutions and Revenue Cycle Management Market (RCM) business is becoming increasingly competitive, Subramanian believes there is a lot of room for growth and the company will be able to maintain its lead.
“We are differentiating because of the platform we have to offer. Second, we have to be able to mature the data types of technology faster than new players [and] The deep relationship we have. ” she said.
Key Points
- The total addressable market for the U.S. healthcare industry is $222 billion, outsourcing $34 billion, an increase of 12%. IKS Health aims to exceed this growth rate.
- The company publishes revenue ₹For fiscal year 266.4 million, a year-on-year increase of 47%, and a healthy EBITDA margin of 30%.
- IKS Health is investing in AI to enhance automation of its products, with revenues from R&D expenditures of 4.5-5.0%.
- The company is integrating the acquired company’s water solutions by moving operations of human onshore services to more automated and offshore processes, thus expanding service capabilities.
- In the U.S., the Trump administration’s focus on cutting health care costs provides IK with a favorable environment as customers seek cost-saving solutions that increase demand for their platform.
